Wedbush Securities’s Argos Therapeutics, Inc. ARGS Stock Holding History

Wedbush Securities’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-78,000	Closed	-$13K	–	967
2018 Q2	$13K	Buy	78,000 +35,000	+81%	+$27.1K	﹤0.01%	873
2018 Q1	$39K	Buy	43,000 +35,400	+466%	+$66.3K	0.01%	795
2017 Q4	$23K	Buy	7,600 +2,000	+36%	+$6.71K	﹤0.01%	841
2017 Q3	$20K	Buy	5,600 +1,125	+25%	+$5.39K	﹤0.01%	825
2017 Q2	$32K	Buy	4,475 +1,300	+41%	+$11.1K	﹤0.01%	817
2017 Q1	$29K	Buy	+3,175	New	+$201K	﹤0.01%	821

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Wedbush Securities's ARGS Position: Q3 2018 in Review

Wedbush Securities sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2018, closing a stake of 78,000 shares — an estimated $13K sold.

Wedbush Securities first reported a position in ARGS in Q1 2017 and held it in 6 quarters. The position peaked at $39K in Q1 2018. 1 fund tracked by Wall St. Rank holds ARGS as of Q3 2018.

Wedbush Securities reported no remaining Argos Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Wedbush Securities sold 78,000 Argos Therapeutics, Inc. shares in Q3 2018, an estimated $13K.
Wedbush Securities first reported a position in Argos Therapeutics, Inc. in Q1 2017 and held it in 6 quarters.
Wedbush Securities's Argos Therapeutics, Inc. position peaked at $39K in Q1 2018.
1 fund tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2018.

Based on Wedbush Securities's 13F filing for Q3 2018, filed 13 Nov 2018.